The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant
The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.
Dr Rupali Paranjape, an experienced regulatory and compliance consultant and author of Blue Ocean of Compliance shares insights on her book in an interview with Thomas C Thottathil, Editor, www.indianpharmapost.com
Expected to open later this year, the facility will significantly increase distribution capacity to meet the growing demand for production materials by Ireland's biopharma industry
The FDA is beginning rulemaking to close the “adequate provision” loophole
Maria Soler Nunez appointed as Chief Quality Officer
Brenntag Specialties will provide pharmaceutical manufacturers and biopharmaceutical companies with a reliable supply of high-purity, GMP-compliant acetates
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
Subscribe To Our Newsletter & Stay Updated
